etofylline clofibrate (BioDeep_00000717129)
代谢物信息卡片
化学式: C19H21ClN4O5 (420.12)
中文名称: 依托芬林
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C(=O)OCCN1C=NC2=C1C(=O)N(C(=O)N2C)C)OC3=CC=C(C=C3)Cl
InChI: InChI=1S/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents
D020011 - Protective Agents > D000975 - Antioxidants
D009676 - Noxae > D000963 - Antimetabolites
D011838 - Radiation-Sensitizing Agents
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:135681
- KEGGdrug: D06102
- PubChem: 41109
- ChEMBL: CHEMBL1318939
- CAS: 54504-70-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - B Föger, G Tröbinger, A Ritsch, M Lechleitner, T Hopferwieser, H J Menzel, G Utermann, K P Pfeiffer, J R Patsch. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition.
Atherosclerosis.
1995 Oct; 117(2):253-61. doi:
10.1016/0021-9150(95)05580-p. [PMID: 8801871] - E Rajecová, I Klimes, E Seböková, E Rychnavská, L Pleváková, A Linke-Cvrkalová, H Langrová. [Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
Vnitrni lekarstvi.
1995 Oct; 41(10):677-81. doi:
NULL. [PMID: 8578698] - K Raslová, M Hucková. [Etophylline clofibrate in the treatment of familial combined hyperlipoproteinemia].
Vnitrni lekarstvi.
1995 Apr; 41(4):240-2. doi:
". [PMID: 7762188] - J Hrebícek, N Skottová, Z Chmela, M Hrbková. [Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia].
Casopis lekaru ceskych.
1995 Mar; 134(5):141-4. doi:
NULL. [PMID: 7728839] - H Wilczek, J Sobra, R Ceska, V Justová, R Procházková, M Kvasilová, Z Jůzová. [Therapy with fibrates and vitamin D metabolism].
Casopis lekaru ceskych.
1993 Oct; 132(20):630-2. doi:
NULL. [PMID: 8269466] - H Toschnerová, R Ceska, J Sobra, J Traurig. [Duolip Forte--experience during a 6-month period of administration].
Casopis lekaru ceskych.
1993 May; 132(10):308-10. doi:
". [PMID: 8513467] - L Kłosiewicz-Latoszek, W B Szostak. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
European journal of clinical pharmacology.
1991; 40(1):33-41. doi:
10.1007/bf00315136. [PMID: 2060543] - R Ceska, J Sobra, R Procházková, M Kvasilová. [Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Vnitrni lekarstvi.
1990 Apr; 36(4):363-7. doi:
". [PMID: 2356612] - W Haberbosch, A Gnasso, W Ziegler, J Augustin. The effect of etophylline clofibrate on HDL subfractions.
Atherosclerosis.
1985 Apr; 55(1):71-80. doi:
10.1016/0021-9150(85)90167-4. [PMID: 4004984] - R Scherhag. [Modification of serum uric acid concentration under long-term therapy with the lipid-regulating drug Duolip].
Fortschritte der Medizin.
1983 Sep; 101(36):1635-7. doi:
NULL. [PMID: 6629296] - G Fiegel. [Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
Die Medizinische Welt.
1982 Mar; 33(9):334-6. doi:
". [PMID: 7045566] - J E Davies, D N Kellett. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
Arzneimittel-Forschung.
1980; 30(11b):2035-7. doi:
. [PMID: 7194055] - P W Lücker, K Wetzelsberger, W Erking, M Donike. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
Arzneimittel-Forschung.
1980; 30(11b):2045-53. doi:
NULL. [PMID: 7194058] - W A Ritschel, G A Thompson, P W Lücker, K Wetzelsberger. Biopharmaceutic evaluation of etofylline clofibrate and its drug formulation.
Arzneimittel-Forschung.
1980; 30(11b):2020-3. doi:
NULL. [PMID: 7194052] - J Schneider, G Mühlfellner, O Mühlfellner, L Hausmann, R Schubotz. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Arzneimittel-Forschung.
1980; 30(11b):2059-62. doi:
NULL. [PMID: 7194060] - W J Ziegler. [On the uricosuric activity of etofylline clofibrate (author's transl)].
Arzneimittel-Forschung.
1980; 30(11b):2073-4. doi:
NULL. [PMID: 7194063] - W J Ziegler, G Metz, M Specker. [Clinical effects and tolerance of etofylline clofibrate].
Arzneimittel-Forschung.
1980; 30(11b):2053-8. doi:
". [PMID: 7194059] - H H Ditschuneit, V Hutt, H U Klör, H Ditschuneit. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Arzneimittel-Forschung.
1980; 30(11b):2063-7. doi:
". [PMID: 7194061]
